 Hello Immunization Partners,
Please share the following information with staff and colleagues.
On June 27, 2024, the Advisory Committee on Immunization Practices (ACIP) recommended 21-valent PCV (PCV21) as an option for adults aged 19 years and older who are currently recommended to receive PCV15 or PCV20. The indications for PCV have not changed since they were previously published.
PCV21 contains 8 serotypes not included in PCV15, PCV20, or PPSV23. However, PCV21 doesn’t contain certain pneumococcal serotypes (e.g., serotype 4) included in other pneumococcal vaccines.
In certain adult populations in the western United States (Alaska, Colorado, New Mexico, Navajo Nation, and Oregon), serotype 4 has caused high percentages (i.e., ≥30%) of invasive pneumococcal disease (IPD). It is currently unknown if this is seen in other parts of the western United States that don’t routinely monitor IPD data.
Typically, individuals living within these geographic areas who develop serotype 4 IPD are adults under the age of 65 years with specific underlying conditions or risk factors such as alcoholism, chronic lung disease, cigarette smoking, homelessness, and injection drug use. Importantly, these individuals usually haven’t received a PCV containing serotype 4. In such populations, other recommended pneumococcal vaccines (e.g., PCV20 alone or both PCV15 and PPSV23 in series) are expected to provide broader serotype coverage against locally circulating strains compared to PCV21 alone.
This clinical guidance will be reviewed and updated as pneumococcal disease epidemiology evolves.
These resources have been updated to include PCV21:
Pneumococcal Vaccine Timing for Adults (cdc.gov)
PneumoRecs VaxAdvisor (cdc.gov)
Thank you for following our immunization updates.
Oakland County Health Division, Immunization Action Plan
|
